BioAtla to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla to Participate in Upcoming Investor Conferences in August
August 03, 2023 16:01 ET
|
BioAtla, Inc.
SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Reports Second Quarter 2023 Financial Results and Highlights Recent Progress
August 01, 2023 16:01 ET
|
BioAtla, Inc.
Achieved first patient in (FPI) and continuing to enroll CAB-AXL BA3011 in a Phase 2 potentially registrational study in Undifferentiated Pleomorphic Sarcoma (UPS) Submitted Food & Drug...
BioAtla to Announce Second Quarter 2023 Financial Results and Provide Business Highlights on August 1, 2023
July 25, 2023 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, July 25, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Added to Membership of U.S. Small-Cap Russell 2000® Index
June 26, 2023 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla to Participate in the Jefferies Healthcare Conference
May 31, 2023 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Reports First Quarter 2023 Financial Results and Highlights Recent Progress
May 11, 2023 16:01 ET
|
BioAtla, Inc.
Advancing CAB-AXL BA3011 in ongoing sarcoma Phase 2 studies including a potentially registrational study in Undifferentiated Pleomorphic Sarcoma (UPS); expect Leiomyosarcoma (LMS) cohort readout in...
BioAtla to Participate in the JMP Securities Life Sciences Conference
May 08, 2023 16:05 ET
|
BioAtla, Inc.
SAN DIEGO, May 08, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023
May 04, 2023 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress
March 23, 2023 16:05 ET
|
BioAtla, Inc.
- Cleared dose-limiting toxicity (DLT) observation period with more frequent, dose-intensive regimen of CAB-AXL BA3011; anticipated leiomyosarcoma (LMS) cohort readout in 2H23 - Initiated the...